BioCentury | Oct 24, 2019
Preclinical News

Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more

Broad influenza protection by human antibodies against neuraminidase A Science study from Scripps Research Institute, Icahn School of Medicine at Mount Sinai and Washington University in St. Louis identified three human antibodies that could serve...
BioCentury | May 15, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Mouse studies suggest a fusion protein-based vaccine plus a STING-activating cyclic dinucleotide (CDN) adjuvant could help prevent tuberculosis (TB). The fusion protein consists of five Mycobacterium tuberculosis antigens: fbpB, esxA, hrp1, rpfD and...
BioCentury | Feb 6, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Tuberculosis Non-human primate studies suggest a vaccine based on cytomegalovirus (CMV) expressing six M. tuberculosis antigens could help prevent tuberculosis (TB). The vaccine consists of six bacterial antigens -- M. tuberculosis fbpA, esxA, vapB47,...
BioCentury | Mar 8, 2017
Distillery Therapeutics


INDICATION: Adjuvant Cell culture and mouse studies suggest a synthetic glycolipid adjuvant could help improve the efficacy of vaccines for infectious diseases with less toxicity than conventional adjuvants. In human monocytes and mouse monocyte-derived dendritic...
BioCentury | Mar 2, 2017
Translation in Brief

Polyester protection

A vaccine based on engineered biobeads offers a new paradigm for immunization against tuberculosis that incorporates both known and unknown antigens to mimic the broad repertoire of live vaccines, but with the safety of non-infectious...
BioCentury | Aug 28, 2014
Distillery Techniques

Technology: Drug platforms

...tuberculosis secreted antigen 85-C (fbpC; ag85C) The crystal structures of thiol-reactive agents in complex with fbpC...
...aid the rational design of new therapeutic candidates to treat tuberculosis. The crystal structures of fbpC...
...the thiol-reactive agents interacted with the fbpC active site. An additional four crystal structures of fbpC...
BioCentury | Nov 18, 2013
Clinical News

AERAS-456: Phase I/IIa started

Not-for-profit Aeras and the Danish government institute said the South African Tuberculosis Vaccine Initiative (SATVI) began a 2-part, double-blind, South African Phase I/IIa trial to evaluate 3 doses of AERAS-456 containing 5, 15 or 50...
BioCentury | Apr 15, 2013
Clinical News

Innogenetics NV regulatory update

INNX received European Patent No. 92903939.4 covering the 85C antigen of Mycobacterium tuberculosis (TB). INNX sells a test that confirms the presence of TB and detects the possible resistance of M. tuberculosis strains to the...
BioCentury | Jan 16, 2012
Clinical News

Tuberculosis vaccine: Phase II started

Intercell said Statens Serum Institut (Copenhagen, Denmark) began a double-blind, South African and Tanzanian Phase II trial to evaluate 2 doses of H1IC in HIV-infected patients. The European and Developing Countries Clinical Trials Partnership (EDCTP)...
BioCentury | Feb 17, 2011
Targets & Mechanisms

Protecting against latent TB

A team of EU and U.S. researchers has created a subunit vaccine based on three Mycobacterium tuberculosis antigens and shown that it protects healthy mice from tuberculosis and prevents reactivation of disease in mouse models...
Items per page:
1 - 10 of 17